| [1] | SHATTOCK A J, JOHNSON H C, SIM S Y, et al. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization[J]. Lancet, 2024, 403(10441): 2307-2316. doi: 10.1016/S0140-6736(24)00850-X |
| [2] | PARKER E P, MOLODECKY N A, PONS-SALORT M, et al. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame[J]. Expert Rev Vaccines, 2015, 14(8): 1113-1123. doi: 10.1586/14760584.2015.1052800 |
| [3] | ISLAM M A, FIRDOUS J, BADRUDDOZA A Z M, et al. M cell targeting engineered biomaterials for effective vaccination[J]. Biomaterials, 2019, 192: 75-94. doi: 10.1016/j.biomaterials.2018.10.041 |
| [4] | DU G S, QIN M, SUN X. Recent progress in application of nanovaccines for enhancing mucosal immune responses[J]. Acta Pharm Sin B, 2023, 13(6): 2334-2345. doi: 10.1016/j.apsb.2022.08.010 |
| [5] | KUNISAWA J, KURASHIMA Y, KIYONO H. Gut-associated lymphoid tissues for the development of oral vaccines[J]. Adv Drug Deliv Rev, 2012, 64(6): 523-530. doi: 10.1016/j.addr.2011.07.003 |
| [6] | LELOUARD H, FALLET M, DE BOVIS B, et al. Peyer’s patch dendritic cells sample antigens by extending dendrites through M cell-specific transcellular pores[J]. Gastroenterology, 2012, 142(3): 592-601. |
| [7] | XU Y N, SHRESTHA N, PRÉAT V, et al. Overcoming the intestinal barrier: a look into targeting approaches for improved oral drug delivery systems[J]. J Control Release, 2020, 322: 486-508. doi: 10.1016/j.jconrel.2020.04.006 |
| [8] | DES RIEUX A, RAGNARSSON E G E, GULLBERG E, et al. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium[J]. Eur J Pharm Sci, 2005, 25(4-5): 455-465. doi: 10.1016/j.ejps.2005.04.015 |
| [9] | ZHANG Y D, LI M, DU G S, et al. Advancedoral vaccine delivery strategies for improving the immunity[J]. Adv Drug Deliv Rev, 2021, 177: 113928. doi: 10.1016/j.addr.2021.113928 |
| [10] | MIAO Y B, LIN Y J, CHEN K H, et al. Engineering nano- and microparticles as oral delivery vehicles to promote intestinal lymphatic drug transport[J]. Adv Mater, 2021, 33(51): e2104139. doi: 10.1002/adma.202104139 |
| [11] | LONGET S, LUNDAHL M L E, LAVELLE E C. Targeted strategies for mucosal vaccination[J]. Bioconjug Chem, 2018, 29(3): 613-623. doi: 10.1021/acs.bioconjchem.7b00738 |
| [12] | CLARK M A, BLAIR H, LIANG L, et al. Targeting polymerised liposome vaccine carriers to intestinal M cells[J]. Vaccine, 2001, 20(1-2): 208-217. doi: 10.1016/S0264-410X(01)00258-4 |
| [13] | YEBOAH K G, AKANDE J, ADDO R T, et al. In vitro and ex vivo characterization of lectin-labeled Mycobacterium tuberculosis antigen-containing microspheres for enhanced oral delivery[J]. J Drug Target, 2014, 22(1): 34-47. doi: 10.3109/1061186X.2013.833206 |
| [14] | HASE K, KAWANO K, NOCHI T, et al. Uptake through glycoprotein 2 of FimH(+)bacteria by M cells initiates mucosal immune response[J]. Nature, 2009, 462(7270): 226-230. doi: 10.1038/nature08529 |
| [15] | LING J, LIAO H L, CLARK R, et al. Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance[J]. J Biol Chem, 2008, 283(45): 30585-30595. doi: 10.1074/jbc.M803548200 |
| [16] | KIM S H, YANG I Y, JANG S H, et al. C5a receptor-targeting ligand-mediated delivery of dengue virus antigen to M cells evokes antigen-specific systemic and mucosal immune responses in oral immunization[J]. Microbes Infect, 2013, 15(13): 895-902. doi: 10.1016/j.micinf.2013.07.006 |
| [17] | AKASHI S, SAITOH S I, WAKABAYASHI Y, et al. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14[J]. J Exp Med, 2003, 198(7): 1035-1042. |
| [18] | CLARK M A, HIRST B H, JEPSON M A. M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer’s patch M cells[J]. Infect Immun, 1998, 66(3): 1237-1243. doi: 10.1128/IAI.66.3.1237-1243.1998 |
| [19] | MIAO Y B, CHEN K H, CHEN C T, et al. A noninvasive gut-to-brain oral drug delivery system for treating brain tumors[J]. Adv Mater, 2021, 33(34): e2100701. doi: 10.1002/adma.202100701 |
| [20] | HUMPHRIES J D, BYRON A, HUMPHRIES M J. Integrin ligands at a glance[J]. J Cell Sci, 2006, 119(Pt 19): 3901-3903. |
| [21] | KIM S H, JUNG D I, YANG I Y, et al. Application of an M-cell-targeting ligand for oral vaccination induces efficient systemic and mucosal immune responses against a viral antigen[J]. Int Immunol, 2013, 25(11): 623-632. doi: 10.1093/intimm/dxt029 |
| [22] | YOO M K, KANG S K, CHOI J H, et al. Targeted delivery of chitosan nanoparticles to Peyer’s patch using M cell-homing peptide selected by phage display technique[J]. Biomaterials, 2010, 31(30): 7738-7747. doi: 10.1016/j.biomaterials.2010.06.059 |
| [23] | LI W Q, YANG X, WANG M F, et al. Development of a cascade-targeting oral vaccine via glycoprotein 2 on intestinal microfold cells for cancer immunotherapy[J]. Nano Lett, 2025, 25(13): 5165-5173. doi: 10.1021/acs.nanolett.4c06123 |
| [24] | SHIMA H, WATANABE T, FUKUDA S, et al. A novel mucosal vaccine targeting Peyer’s patch M cells induces protective antigen-specific IgA responses[J]. Int Immunol, 2014, 26(11): 619-625. doi: 10.1093/intimm/dxu061 |
| [25] | ROCHEREAU N, PAVOT V, VERRIER B, et al. Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity[J]. J Allergy Clin Immunol, 2016, 137(1): 214-222. |
| [26] | ROCHEREAU N, MICHAUD E, WAECKEL L, et al. Essential role of TOSO/FAIM3 in intestinal IgM reverse transcytosis[J]. Cell Rep, 2021, 37(7): 110006. doi: 10.1016/j.celrep.2021.110006 |
| [27] | LUO P K, CHANG W N, PENG S Y, et al. Endogenous macrophages as “Trojan horses” for targeted oral delivery of mRNA-encoded cytokines in tumor microenvironment immunotherapy[J]. Biomaterials, 2026, 325: 123620. doi: 10.1016/j.biomaterials.2025.123620 |
| [28] | XIN X F, WU D, ZHAO P B, et al. Catch-to-amplify nanoparticles with bacteria surface for sequential mucosal immune activation for acute myeloid leukemia therapy[J]. ACS Nano, 2025, 19(15): 14661-14679. doi: 10.1021/acsnano.4c08515 |
| [29] | NGUYEN N, HOANG T M, HUANG T, et al. Macrophage-hitchhiked, effervescence-induced nanoemulsions for enhanced oral chemotherapy and immunotherapy: Impact on absorption route[J]. Biomaterials, 2025, 316: 123019. doi: 10.1016/j.biomaterials.2024.123019 |
| [30] | WANG C F, TANG H B, DUAN Y F, et al. Oral biomimetic virus vaccine hydrogel for robust abscopal antitumour efficacy[J]. J Colloid Interface Sci, 2024, 674: 92-107. doi: 10.1016/j.jcis.2024.06.102 |
| [31] | NGUYEN V K, NGUYEN N, LI Z C, et al. Inflammation-activated endogenous macrophage-mediated prodrug delivery system overcoming biological barriers for enhanced oral meningitis therapy[J]. Adv Funct Mater, 2024, 34(32): 2401570. doi: 10.1002/adfm.202401570 |
| [32] | SIBORO P Y, NGUYEN N, LO S K, et al. Innate immunity-guided macrophage-homing nanoplatform for oral tumor immunotherapy and real-time deep-tissue imaging in pre-clinical models[J]. Adv Mater, 2025, 37(40): e07607. doi: 10.1002/adma.202507607 |
| [33] | CHEN Z, QIN Y T, LI Q R, et al. Layer-by-layer deposition of antigen peptides on Bifidobacterium for subintestinal lymphatic system-guided personalized tumor immunotherapy[J]. Adv Mater, 2025, 37(26): e2503571. doi: 10.1002/adma.202503571 |
| [34] | CHEN X N, SHI T F, CHEN F M, et al. Orally antigen-engineered yeast vaccine elicits robust intestinal mucosal immunity[J]. ACS Nano, 2025, 19(11): 10841-10853. doi: 10.1021/acsnano.4c14690 |
| [35] | LI J X, YANG R Q, YUAN Y H, et al. An oral nanovaccine secreted by genetically engineered and ultrasound-responsive bacteria for colon cancer immunotherapy[J]. Adv Funct Mater, 2025, 35(6): 2414994. doi: 10.1002/adfm.202414994 |